1. severe or critical covid-19. 2. spo2≤93% on room air at sea level or pao2/fio2≤ 300 (with oxygen inhalation), or respiratory rate ≥30 per minute, or heart rate ≥125 per minute. 3. require mechanical ventilation or anticipated impending need for mechanical ventilation. 4. are suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention. 5. current eye disease (such as inflammation, vessel deformity, retinal hemorrhage or decollement, optic nerve lesion, or fundus lesion). 6. alt or ast\>2 uln at screening. 7. allergies to any of the components used in the formulation of the interventions. 8. any medical condition, which in the opinion of the investigator, will compromise the safety of the participant. 9. received a sars-cov-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) within 30 days prior to screening. 10. received convalescent covid-19 plasma treatment within 30 days prior to screening. 11. participated in a clinical study involving an investigational intervention within the last 30 days. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. 12. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. 13. female who are pregnant or breast-feeding or plan to be pregnant within this study period.

1. severe or critical covid-19. 2. spo2≤93% on room air at sea level or pao2/fio2≤ 300 (with oxygen inhalation), or respiratory rate ≥30 per minute, or heart rate ≥125 per minute. 3. require mechanical ventilation or anticipated impending need for mechanical ventilation. 4. are suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention. 5. current eye disease (such as inflammation, vessel deformity, retinal hemorrhage or decollement, optic nerve lesion, or fundus lesion). 6. alt or ast\>2 uln at screening. 7. allergies to any of the components used in the formulation of the interventions. 8. any medical condition, which in the opinion of the investigator, will compromise the safety of the participant. 9. received a sars-cov-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) within 30 days prior to screening. 10. received convalescent covid-19 plasma treatment within 30 days prior to screening. 11. participated in a clinical study involving an investigational intervention within the last 30 days. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. 12. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. 13. female who are pregnant or breast-feeding or plan to be pregnant within this study period.

severe or critical covid-19. spo2≤93% on room air at sea level or pao2/fio2≤ 300 (with oxygen inhalation), or respiratory rate ≥30 per minute, or heart rate ≥125 per minute. require mechanical ventilation or anticipated impending need for mechanical ventilation. are suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention. current eye disease (such as inflammation, vessel deformity, retinal hemorrhage or decollement, optic nerve lesion, or fundus lesion). alt or ast>2 uln at screening. allergies to any of the components used in the formulation of the interventions. any medical condition, which in the opinion of the investigator, will compromise the safety of the participant. received a sars-cov-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) within 30 days prior to screening. received convalescent covid-19 plasma treatment within 30 days prior to screening. participated in a clinical study involving an investigational intervention within the last 30 days. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. female who are pregnant or breast-feeding or plan to be pregnant within this study period.

severe or critical covid-19. spo2≤93% on room air at sea level or pao2/fio2≤ 300 (with oxygen inhalation), or respiratory rate ≥30 per minute, or heart rate ≥125 per minute. require mechanical ventilation or anticipated impending need for mechanical ventilation. are suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention. current eye disease (such as inflammation, vessel deformity, retinal hemorrhage or decollement, optic nerve lesion, or fundus lesion). alt or ast>2 uln at screening. allergies to any of the components used in the formulation of the interventions. any medical condition, which in the opinion of the investigator, will compromise the safety of the participant. received a sars-cov-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment) within 30 days prior to screening. received convalescent covid-19 plasma treatment within 30 days prior to screening. participated in a clinical study involving an investigational intervention within the last 30 days. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. female who are pregnant or breast-feeding or plan to be pregnant within this study period.